FILING ANALYSIS · THURSDAY, NOVEMBER 5
Avalo Therapeutics, Inc. AVTX — 8-K: Results of Operations and Financial Condition
neutral
Avalo Therapeutics reported a net loss of $18.9 million for the third quarter of 2026, with cash, cash equivalents, and investments of $462.8 million, expected to fund operations into 2029. The company is advancing its abdakibart and AVTX-010 programs, with a registrational Phase 3 program for abdakibart planned for the first half of 2027.
How we read impact: we grade every directional call in the open. Impact labels are AI estimates — not investment advice. See the full disclaimer.
Get filings like this every market day
The US SEC filings, UK RNS, EU notices, and Polymarket odds that matter — scored by AI, in one email.
Subscribe free →